Fresh Equities
Raises
Research
About
Looking for more information?

Contact our responsive and friendly client services team any time.

(03) 9028 2888

clients@freshequities.com

Botanix Pharmaceuticals Ltd

Investor presentation - Botanix Pharmaceuticals Ltd

ASX:BOT

Botanix Pharmaceuticals Ltd

Health

Botanix Pharma aims to develop​ next-generation therapeutics for the treatment of serious skin diseases. The company's mission is to improve the lives of patients battling acne, psoriasis and atopic dermatitis, by providing new treatment options for conditions that currently are inadequately addressed or are treated with therapeutics that are burdened with side effects profiles. The company is developing the potential of a synthetic active pharmaceutical ingredient known as cannabidiol which is currently being studied for the treatment of epilepsy, pain, arthritis and schizophrenia amongst other indications. Botanix is preparing for the first human trials utilizing synthetic cannabidiol in a proprietary drug delivery system (Permetrex™) for direct skin delivery of the therapy.

Read more

Market Cap

$165.43m

Price at Close

$0.17

4w avg. Volume

3.89m

4w avg. Turnover

$568.07k

Announcements
announcementt+2 movementdate
  • Appendix 4C - Quarterly

    Commitments test entity quarterly reports · Market sensitive

  • -

    22 Jan 2021

-

22 Jan 2021
  • Antimicrobial Data Published in Peer-Reviewed Journal

    Progress Report · Market sensitive

  • +22.22%

    19 Jan 2021

+22.22%

19 Jan 2021
  • Appendix 2A and Notice Under Section 708A

    Issued Capital

  • +4.17%

    17 Dec 2020

+4.17%

17 Dec 2020
  • Update on BTX 1801 Phase 2a Clinical Study

    Progress Report · Market sensitive

  • -7.69%

    13 Dec 2020

-7.69%

13 Dec 2020
  • Results of Meeting

    Notice Of Meeting

  • -7.69%

    23 Nov 2020

-7.69%

23 Nov 2020
  • AGM Presentation

    Periodic Reports

  • -7.69%

    23 Nov 2020

-7.69%

23 Nov 2020
  • FDA Clears Development Path for BTX 1801

    Progress Report · Market sensitive

  • +10.53%

    10 Nov 2020

+10.53%

10 Nov 2020
  • Letter to Shareholders - AGM

    Notice Of Meeting

  • +6.38%

    21 Oct 2020

+6.38%

21 Oct 2020
  • Notice of Annual General Meeting/Proxy Form

    Notice Of Meeting

  • +6.38%

    21 Oct 2020

+6.38%

21 Oct 2020
  • Appendix 4C - Quarterly

    Commitments test entity quarterly reports · Market sensitive

  • +10.00%

    12 Oct 2020

+10.00%

12 Oct 2020
Market Data

Current Price

$0.17

52WK HIGH

$0.18

52WK LOW

$0.023

1YR RETURN

+82.80%

1YR RETURN VS. SECTOR

+44.11%

90 DAY RETURN

+70.00%

ASX RANK

688

/2,048

SECTOR RANK

60

/168

SHARES OUTSTANDING

973.14m
ASX:BOT

Botanix Pharmaceuticals Ltd

Health

Botanix Pharma aims to develop​ next-generation therapeutics for the treatment of serious skin diseases. The company's mission is to improve the lives of patients battling acne, psoriasis and atopic dermatitis, by providing new treatment options for conditions that currently are inadequately addressed or are treated with therapeutics that are burdened with side effects profiles. The company is developing the potential of a synthetic active pharmaceutical ingredient known as cannabidiol which is currently being studied for the treatment of epilepsy, pain, arthritis and schizophrenia amongst other indications. Botanix is preparing for the first human trials utilizing synthetic cannabidiol in a proprietary drug delivery system (Permetrex™) for direct skin delivery of the therapy.

Read more

Market Cap

$165.43m

Price at Close

$0.17

4w avg. Volume

3.89m

4w avg. Turnover

$568.07k

ASX:BOT is not raising right now

Want to invest?

Fresh Equities

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.

Contact Us

(03) 9028 2888

clients@freshequities.com

Address

Level 7, 388 Bourke St
Melbourne VIC 3000
Australia

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.